SGLT2i与GLP-1RA心血管结局的种族差异荟萃分析
该系统综述与随机效应荟萃分析汇总了2015至2020年PubMed收录的SGLT2i和GLP-1RA心血管结局试验,按亚洲人与白人分层比较。结果显示,在HFrEF患者中SGLT2i对心血管死亡/心衰住院的获益亚洲人可能更大,在2型糖尿病患者中GLP-1RA对MACE的获益亚洲人可能更大。
要点
- HFrEF患者中SGLT2i的心血管死亡/心衰住院获益亚洲人可能优于白人。
- 2型糖尿病患者中GLP-1RA的MACE获益亚洲人可能优于白人。
- SGLT2i对2型糖尿病MACE的获益未显示显著种族交互作用。
核心结论
- 与白人相比,亚洲HFrEF患者使用SGLT2i可能获得更大的心血管死亡/心衰住院获益。
- 与白人相比,亚洲2型糖尿病患者使用GLP-1RA可能获得更大的MACE获益。
研究设计与样本
- 纳入报告亚裔与白人HR(95%CI)的SGLT2i和GLP-1RA随机安慰剂对照心血管结局试验。
主要发现
- 四项SGLT2i 2型糖尿病试验中,MACE的HR在3,298名亚洲人为0.81(0.57, 1.04),在20,258名白人为0.90(0.80, 1.00),P交互=0.46。
- 两项SGLT2i HFrEF试验中,心血管死亡/心衰住院的HR在1,788名亚洲人为0.60(0.47, 0.74),在5,962名白人为0.82(0.73, 0.92),P交互=0.01。
- 六项GLP-1RA试验中,MACE的HR在4,195名亚洲人为0.68(0.53, 0.84),在37,530名白人为0.87(0.81, 0.94),P交互=0.03。
临床怎么用
- 在HFrEF合并2型糖尿病的亚洲患者中,可优先考虑SGLT2i以降低心血管死亡和心衰住院风险。
- 在2型糖尿病的亚洲患者中,GLP-1RA可能带来更显著的MACE获益,选择降糖药物时可结合种族差异考量。
局限性
- 缺乏个体患者水平数据。
- 试验观察时间相对较短。
- 亚洲亚组内缺乏细化的种族分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results of cardiovascular outcome trials (CVOTs) suggest Asians may derive greater benefit than Whites from newer classes of antihyperglycemic medications. PURPOSE: To provide summary hazard ratio (HR) estimates for cardiovascular efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) stratified by race (Asian vs. White). DATA SOURCES: A systematic review performed in PubMed from 1 January 2015 to 8 December 2020. STUDY SELECTION: Randomized placebo-controlled CVOTs of SGLT2is and GLP-1RAs that reported HRs (95% CIs) for 1) major adverse cardiovascular event (MACE) in patients with diabetes and 2) cardiovascular (CV) death/hospitalization for heart failure (HHF) in patients with HF and reduced ejection fraction (HFrEF). DATA EXTRACTION AND SYNTHESIS: HRs (95% CIs) for selected outcomes in Asians and Whites were extracted from each trial, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Random-effects meta-analyses were performed to examine differences between the selected outcomes in Asians versus Whites. RESULTS: In four SGLT2i trials in type 2 diabetes, the MACE outcome HR (95% CI) in 3,298 Asians versus 20,258 Whites was 0.81 (0.57, 1.04) vs. 0.90 (0.80, 1.00), respectively (P interaction = 0.46). In two SGLT2i trials in patients with HFrEF, the CV death/HHF outcome HR in 1,788 Asians versus 5,962 Whites was 0.60 (0.47, 0.74) vs. 0.82 (0.73, 0.92), respectively (P interaction = 0.01). In six GLP-1RA trials, the MACE outcome HR in 4,195 Asians versus 37,530 Whites was 0.68 (0.53, 0.84) vs. 0.87 (0.81, 0.94), respectively (P interaction = 0.03). LIMITATIONS: Lack of individual patient-level data, relatively short duration of trial observation, and lack of granular categorization of race within broadly defined Asian subgroups. CONCLUSIONS: Compared with Whites, Asians may derive greater CV death/HHF benefit from SGLT2is in patients with HFrEF, and MACE benefit from GLP-1RAs in patients with type 2 diabetes.
引用
- Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care. 2021. PMID: 33707305. doi:10.2337/dc20-3007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。